The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

Research output: Contribution to journalArticle

Standard

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. / Burnett, AK; Hills, RK; Hunter, A; Milligan, Donald; Kell, J; Wheatley, Keith; Yin, J; McMullin, MF; Cahalin, P; Craig, J; Bowen, D; Russell, N.

In: Leukemia, Vol. 25, No. 7, 01.07.2011, p. 1122-1127.

Research output: Contribution to journalArticle

Harvard

Burnett, AK, Hills, RK, Hunter, A, Milligan, D, Kell, J, Wheatley, K, Yin, J, McMullin, MF, Cahalin, P, Craig, J, Bowen, D & Russell, N 2011, 'The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome', Leukemia, vol. 25, no. 7, pp. 1122-1127. https://doi.org/10.1038/leu.2011.59

APA

Burnett, AK., Hills, RK., Hunter, A., Milligan, D., Kell, J., Wheatley, K., Yin, J., McMullin, MF., Cahalin, P., Craig, J., Bowen, D., & Russell, N. (2011). The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia, 25(7), 1122-1127. https://doi.org/10.1038/leu.2011.59

Vancouver

Author

Burnett, AK ; Hills, RK ; Hunter, A ; Milligan, Donald ; Kell, J ; Wheatley, Keith ; Yin, J ; McMullin, MF ; Cahalin, P ; Craig, J ; Bowen, D ; Russell, N. / The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. In: Leukemia. 2011 ; Vol. 25, No. 7. pp. 1122-1127.

Bibtex

@article{3f19f5701622426490fb72bb25bd2219,
title = "The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome",
abstract = "Most patients with acute myeloid leukaemia (AML) are older, with many unsuitable for conventional chemotherapy. Low-dose Ara-C (LDAC) is superior to best supportive care but is still inadequate. The combination of arsenic trioxide (ATO) and LDAC showed promise in an unrandomised study. We report a randomised trial of LDAC versus LDAC + ATO. Patients with AML according to WHO criteria or myelodysplastic syndrome with > 10% blasts, considered as unfit for conventional chemotherapy, were randomised between subcutaneous Ara-C (20mg b.d. for 10 days) and the same LDAC schedule with ATO (0.25 mg/kg) on days 1-5, 9 and 11, for at least four courses every 4 to 6 weeks. Overall 166 patients were entered; the trial was terminated on the advice of the DMC, as the projected benefit was not observed. Overall 14% of patients achieved complete remission (CR) and 7% CRi. Median survival was 5.5 months and 19 months for responders (CR: not reached; CRi: 14 months; non-responders: 4 months). There were no differences in response or survival between the arms. Grade 3/4 cardiac and liver toxicity, and supportive care requirements were greater in the ATO arm. This randomised comparison demonstrates that adding ATO to LDAC provides no benefit for older patients with AML. Leukemia (2011) 25, 1122-1127; doi:10.1038/leu.2011.59; published online 8 April 2011",
keywords = "arsenic trioxide, clinical trials, acute myeloid leukaemia",
author = "AK Burnett and RK Hills and A Hunter and Donald Milligan and J Kell and Keith Wheatley and J Yin and MF McMullin and P Cahalin and J Craig and D Bowen and N Russell",
year = "2011",
month = jul,
day = "1",
doi = "10.1038/leu.2011.59",
language = "English",
volume = "25",
pages = "1122--1127",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

RIS

TY - JOUR

T1 - The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

AU - Burnett, AK

AU - Hills, RK

AU - Hunter, A

AU - Milligan, Donald

AU - Kell, J

AU - Wheatley, Keith

AU - Yin, J

AU - McMullin, MF

AU - Cahalin, P

AU - Craig, J

AU - Bowen, D

AU - Russell, N

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Most patients with acute myeloid leukaemia (AML) are older, with many unsuitable for conventional chemotherapy. Low-dose Ara-C (LDAC) is superior to best supportive care but is still inadequate. The combination of arsenic trioxide (ATO) and LDAC showed promise in an unrandomised study. We report a randomised trial of LDAC versus LDAC + ATO. Patients with AML according to WHO criteria or myelodysplastic syndrome with > 10% blasts, considered as unfit for conventional chemotherapy, were randomised between subcutaneous Ara-C (20mg b.d. for 10 days) and the same LDAC schedule with ATO (0.25 mg/kg) on days 1-5, 9 and 11, for at least four courses every 4 to 6 weeks. Overall 166 patients were entered; the trial was terminated on the advice of the DMC, as the projected benefit was not observed. Overall 14% of patients achieved complete remission (CR) and 7% CRi. Median survival was 5.5 months and 19 months for responders (CR: not reached; CRi: 14 months; non-responders: 4 months). There were no differences in response or survival between the arms. Grade 3/4 cardiac and liver toxicity, and supportive care requirements were greater in the ATO arm. This randomised comparison demonstrates that adding ATO to LDAC provides no benefit for older patients with AML. Leukemia (2011) 25, 1122-1127; doi:10.1038/leu.2011.59; published online 8 April 2011

AB - Most patients with acute myeloid leukaemia (AML) are older, with many unsuitable for conventional chemotherapy. Low-dose Ara-C (LDAC) is superior to best supportive care but is still inadequate. The combination of arsenic trioxide (ATO) and LDAC showed promise in an unrandomised study. We report a randomised trial of LDAC versus LDAC + ATO. Patients with AML according to WHO criteria or myelodysplastic syndrome with > 10% blasts, considered as unfit for conventional chemotherapy, were randomised between subcutaneous Ara-C (20mg b.d. for 10 days) and the same LDAC schedule with ATO (0.25 mg/kg) on days 1-5, 9 and 11, for at least four courses every 4 to 6 weeks. Overall 166 patients were entered; the trial was terminated on the advice of the DMC, as the projected benefit was not observed. Overall 14% of patients achieved complete remission (CR) and 7% CRi. Median survival was 5.5 months and 19 months for responders (CR: not reached; CRi: 14 months; non-responders: 4 months). There were no differences in response or survival between the arms. Grade 3/4 cardiac and liver toxicity, and supportive care requirements were greater in the ATO arm. This randomised comparison demonstrates that adding ATO to LDAC provides no benefit for older patients with AML. Leukemia (2011) 25, 1122-1127; doi:10.1038/leu.2011.59; published online 8 April 2011

KW - arsenic trioxide

KW - clinical trials

KW - acute myeloid leukaemia

U2 - 10.1038/leu.2011.59

DO - 10.1038/leu.2011.59

M3 - Article

C2 - 21475252

VL - 25

SP - 1122

EP - 1127

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -